SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS
Conditions: Ovarian Cancer Interventions: Procedure: Blood samples Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Conditions: Recurrent Ovarian Cancer Sponsors: Power Life Sciences Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer Interventions: Other: Biological sample collection Sponsors: Exscientia GmbH; AGO Research GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
Conditions: Premature Ovarian Insufficiency Interventions: Drug: hormone replacement therapy Sponsors: Women ' s Hospital School Of Medicine Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Changes in Serum, Follicular Fluid SREBP1c and LRG1 Levels in PCOS Patients and Correlation With Insulin Resistance
Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries Interventions: Diagnostic Test: HOMA-IR ，ESHRE/ASRM Sponsors: Gui Xiaoting Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
Conditions: Ovarian Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: LB-100 Sponsors: M.D. Anderson Cancer Center; GSK Pharma; Lixte Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
Effect of Intravenous Lignocaine Infusion on Intraoperative End Tidal Desflurane Concentration Requirements
Conditions: Cholelithiases; Appendicitis; Ovarian Cysts Interventions: Drug: Lignocaine; Drug: Placebo Sponsors: Universiti Kebangsaan Malaysia Medical Centre Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction
Conditions: Ovarian Cancer Interventions: Procedure: Tumor biopsy Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Effect of Metformin on Healthy Live Birth in Women With Prediabetes
Conditions: Metformin; Prediabetes; In-Vitro Fertilization Interventions: Drug: Metformin pretreatment before ovarian stimulation; Drug: Placebo pretreatment before ovarian stimulation; Drug: Metformin pretreatment before endometrial preparation for frozen embryo transfer; Drug: Placebo pretreatment before endometrial preparation for frozen embryo transfer Sponsors: Shandong University; Ren Ji Hospital of Shanghai Jiao Tong University; Women ' s Hospital of Zhejiang University; Shengjing Hospital; Women ' s Hospital of Nanjing Medical University; General Hospital of Ningxia Medical University; West China Second University ...
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Conditions: Breast Cancer; Ovarian Cancer; Pancreas Cancer; Prostate Cancer; BRCA1 Mutation; BRCA-Mutated Ovarian Carcinoma; BRCA-Associated Breast Carcinoma; HRD Positive Advanced Ovarian Cancer Interventions: Drug: TNG348; Drug: Olaparib Sponsors: Tango Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145
Conditions: Ovarian Cancer Interventions: Drug: KAND145; Drug: Placebo Sponsors: Kancera AB; LINK Medical Research AB; Q&Q Labs AB; CRST Oy Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; High Grade Endometrioid Ovarian Cancer; Primary Peritoneal Cancer; Fallopian-tube Cancer Interventions: Drug: Fluzoparib Capsules; Drug: Bevacizumab Sponsors: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials
Interpersonal Psychotherapy in Adolescents With Polycystic Ovary Syndrome
Conditions: Interpersonal Psychotherapy; Polycystic Ovary Syndrome Intervention: Behavioral: Interpersonal Psychotherapy Sponsors: University of Colorado, Denver; American Psychological Association (APA) Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Interpersonal Psychotherapy in Adolescents With Polycystic Ovary Syndrome
Conditions: Interpersonal Psychotherapy; Polycystic Ovary Syndrome Interventions: Behavioral: Interpersonal Psychotherapy Sponsors: University of Colorado, Denver; American Psychological Association (APA) Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Conditions: Serous Ovarian Cancer; Advanced Ovarian Cancer Interventions: Drug: SC0191; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Biocity Biopharmaceutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
